Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.

Namba M, Katsuno T, Kusunoki Y, Matsuo T, Miuchi M, Miyagawa J.

Clin Exp Nephrol. 2013 Feb;17(1):10-5. doi: 10.1007/s10157-012-0709-0. Epub 2012 Nov 8. Review.

PMID:
23135865
2.

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.

Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.

PMID:
24989141
3.

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.

Boland CL, Degeeter M, Nuzum DS, Tzefos M.

Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Review.

PMID:
23548652
4.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
5.

Incretin therapy and its effect on body weight in patients with diabetes.

Lind M.

Prim Care Diabetes. 2012 Oct;6(3):187-91. doi: 10.1016/j.pcd.2012.04.006. Epub 2012 May 19. Review.

PMID:
22613745
6.

Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.

Seino Y, Kuwata H, Yabe D.

J Diabetes Investig. 2016 Apr;7 Suppl 1:102-9. doi: 10.1111/jdi.12490. Epub 2016 Apr 18. Review.

7.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
8.

Efficacy and safety of incretin based therapies: clinical trial data.

White J.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S30-40. doi: 10.1331/JAPhA.2009.09079. Review.

PMID:
19801363
9.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
10.

Combination pharmacotherapy with incretins: what works best and when?

Over RK, Ratner RE.

Curr Diab Rep. 2008 Oct;8(5):361-7.

PMID:
18778584
11.

Incretin-based therapies in type 2 diabetes mellitus.

Chia CW, Egan JM.

J Clin Endocrinol Metab. 2008 Oct;93(10):3703-16. doi: 10.1210/jc.2007-2109. Epub 2008 Jul 15. Review.

12.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
13.
14.

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ.

Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.

PMID:
19275672
15.

[The value of incretin based therapies].

Gallwitz B.

Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6. Review. German. No abstract available.

PMID:
19421931
16.

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Verspohl EJ.

Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21. Review.

PMID:
19545590
17.
18.
19.

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.

Campbell RK, Cobble ME, Reid TS, Shomali ME.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S20-7.

PMID:
20824236
20.

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.

Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, Xie J, Yang Y, Yu X.

Cardiovasc Diabetol. 2017 Mar 1;16(1):31. doi: 10.1186/s12933-017-0512-z.

Supplemental Content

Support Center